|
1
|
Matsuura Y, Robertson G, Marsden DE, Kim
SN, Gebski V and Hacker NF: Thromboembolic complications in
patients with clear cell carcinoma of the ovary. Gynecol Oncol.
104:406–410. 2007.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Weitz JI, Fredenburgh JC and Eikelboom JW:
A test in context: D-dimer. J Am Coll Cardiol. 70:2411–2420.
2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Hou H, Ge Z, Ying P, Dai J, Shi D, Xu Z,
Chen D and Jiang Q: Biomarkers of deep venous thrombosis. J Thromb
Thrombolysis. 34:335–346. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wells PS, Anderson DR, Rodger M, Forgie M,
Kearon C, Dreyer J, Kovacs G, Mitchell M, Lewandowski B and Kovacs
MJ: Evaluation of D-dimer in the diagnosis of suspected deep-vein
thrombosis. N Engl J Med. 349:1227–1235. 2003.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Andrews EJ Jr and Fleischer AC: Sonography
for deep venous thrombosis: Current and future applications.
Ultrasound Q. 21:213–225. 2005.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kocatürk B and Versteeg HH: Tissue
factor-integrin interactions in cancer and thrombosis: Every Jack
has his Jill. J Thromb Haemost. 11 (Suppl 1):S285–S293.
2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Peraramelli S, Thomassen S, Heinzmann A,
Rosing J, Hackeng TM, Hartmann R, Scheiflinger F and Dockal M:
Inhibition of tissue factor:factor VIIa-catalyzed factor IX and
factor X activation by TFPI and TFPI constructs. J Thromb Haemost.
12:1826–1837. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Fei X, Wang H, Yuan W, Wo M and Jiang L:
Tissue factor pathway inhibitor-1 is a valuable marker for the
prediction of deep venous thrombosis and tumor metastasis in
patients with lung cancer. Biomed Res Int.
2017(8983763)2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sidelmann JJ, Bladbjerg EM, Gram J,
Münster AM and Jespersen J: Tissue factor pathway inhibitor relates
to fibrin degradation in patients with acute deep venous
thrombosis. Blood Coagul Fibrinolysis. 19:405–409. 2008.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Dahm A, Rosendaal FR, Andersen TO and
Sandset PM: Tissue factor pathway inhibitor anticoagulant activity:
Risk for venous thrombosis and effect of hormonal state. Br J
Haematol. 132:333–338. 2006.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Dahm A, Van Hylckama Vlieg A, Bendz B,
Rosendaal F, Bertina RM and Sandset PM: Low levels of tissue factor
pathway inhibitor (TFPI) increase the risk of venous thrombosis.
Blood. 101:4387–4392. 2003.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Amini-Nekoo A, Futers TS, Moia M, Mannucci
PM, Grant PJ and Ariëns RA: Analysis of the tissue factor pathway
inhibitor gene and antigen levels in relation to venous thrombosis.
Br J Haematol. 113:537–543. 2001.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Fedi S, Gori AM, Falciani M, Cellai AP,
Aglietti P, Baldini A, Vena LM, Prisco D, Abbate R and Gensini GF:
Procedure-dependence and tissue factor-independence of
hypercoagulability during orthopaedic surgery. Thromb Haemost.
81:874–878. 1999.PubMed/NCBI
|
|
14
|
Arakawa N, Miyagi E, Nomura A, Morita E,
Ino Y, Ohtake N, Miyagi Y, Hirahara F and Hirano H: Secretome-based
identification of TFPI2, a novel serum biomarker for detection of
ovarian clear cell adenocarcinoma. J Proteome Res. 12:4340–4350.
2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Arakawa N, Kobayashi H, Yonemoto N,
Masuishi Y, Ino Y, Shigetomi H, Furukawa N, Ohtake N, Miyagi Y,
Hirahara F, et al: Clinical significance of tissue factor pathway
inhibitor 2, a serum biomarker candidate for ovarian clear cell
carcinoma. PLoS One. 11(e0165609)2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Miyagi E, Arakawa N, Sakamaki K, Yokota
NR, Yamanaka T, Yamada Y, Yamaguchi S, Nagao S, Hirashima Y,
Kasamatsu Y, et al: Validation of tissue factor pathway inhibitor 2
as a specific biomarker for preoperative prediction of clear cell
carcinoma of the ovary. Int J Clin Oncol. 26:1336–1344.
2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kawaguchi R, Furukawa N and Kobayashi H:
Cut-off value of D-dimer for prediction of deep venous thrombosis
before treatment in ovarian cancer. J Gynecol Oncol. 23:98–102.
2012.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Duska LR, Garrett L, Henretta M, Ferriss
JS, Lee L and Horowitz N: When ‘never-events’ occur despite
adherence to clinical guidelines: The case of venous
thromboembolism in clear cell cancer of the ovary compared with
other epithelial histologic subtypes. Gynecol Oncol. 116:374–377.
2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ebina Y, Uchiyama M, Imafuku H, Suzuki K,
Miyahara Y and Yamada H: Risk factors for deep venous thrombosis in
women with ovarian cancer. Medicine (Baltimore).
97(e11009)2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Bates SM, Jaeschke R, Stevens SM, Goodacre
S, Wells PS, Stevenson MD, Kearon C, Schunemann HJ, Crowther M,
Pauker SG, et al: Diagnosis of DVT: Antithrombotic therapy and
prevention of thrombosis, 9th ed: American college of chest
physicians evidence-based clinical practice guidelines. Chest. 141
(Suppl 2):e351S–e418S. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Geddings JE and Mackman N: Tumor-derived
tissue factor-positive microparticles and venous thrombosis in
cancer patients. Blood. 122:1873–1880. 2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Hoover-Plow J: Does plasmin have
anticoagulant activity? Vasc Health Risk Manag. 6:199–205.
2010.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Medcalf RL: Fibrinolysis: from blood to
the brain. J Thromb Haemost. 15:2089–2098. 2017.PubMed/NCBI View Article : Google Scholar
|
